Imaging The Brain Connectome In Typical And Atypical Development
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
My project will investigate how connections in the brain change during the transition from childhood to adolescence. Advanced neuroimaging techniques will be used to understand how different parts of the brain are connected to one another, and how this changes over time. I will examine typically developing children, as well as those with attention deficit hyperactivity disorder (ADHD) in order to understand how neuropsychiatric disorders affect brain development.
The Genetics Of Cognitive Deficits In Attention Deficit Hyperactivity Disorder (ADHD)
Funder
National Health and Medical Research Council
Funding Amount
$675,512.00
Summary
Attention deficit hyperactivity disorder (ADHD) is a common psychiatric disorder of childhood that is marked by age-inappropriate levels of inattention and-or hyperactivity-impulsivity. The disorder appears genetic with a number of different genes likely contributing risk for ADHD. This project takes an innovative approach by asking whether there are different genetic profiles associated with children with ADHD who do or do not have neurocognitive deficits.
Impact Of A Sleep Intervention In Children With ADHD: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$384,230.00
Summary
Attention deficit hyperactivity disorder (ADHD) affects up to 7.5% of Australian children. Between 50 and 70% of parents also report sleep problems (eg night waking, insomnia) in their child with ADHD. Such sleep problems are associated with poorer child behaviour, concentration, and school attendance as well as poorer parent mental health and work attendance. This randomised controlled trial will determine whether treating sleep problems in children with ADHD can improve these outcomes.
Attention Deficit Hyperactivity Disorder: Genes, Cognition And Brain Activity
Funder
National Health and Medical Research Council
Funding Amount
$428,602.00
Summary
Attention deficit hyperactivity disorder (ADHD) is a common psychiatric disorder of childhood that is marked by age-inappropriate levels of inattention and-or hyperactivity-impulsivity. The disorder appears genetic with a number of different genes likely contributing risk for ADHD. I will use a multi-modal (genetic, cognitive, neurochemical, physiological) approach to increase our understanding of the biological mechanisms leading from gene to disorder in ADHD.
Goal-directed Behaviour In Adolescent ADHD: Neural Connectivity And It’s Significance For Clinical Translation
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Impaired goal-directed decision-making leads to significant difficulties in adolescent attention deficit hyperactivity disorder (ADHD). This research will use novel imaging techniques to study individual-level impairments in brain connectivity in decision making circuits and the effects of common ADHD medications. As these medications are currently prescribed by trial and error, identifying specific connectivity brain signatures will make major contributions to personalised treatment selection.
Imaging Genetics Of Attention Deficit Hyperactivity Disorder (ADHD)
Funder
National Health and Medical Research Council
Funding Amount
$321,767.00
Summary
Attention deficit hyperactivity disorder (ADHD) is a common psychiatric disorder of childhood that is marked by age-inappropriate levels of inattention and-or hyperactivity-impulsivity. The disorder appears genetic with a number of different genes likely contributing risk for ADHD. This project takes an innovative approach by asking how risk genes for ADHD influence the brain activity of children with ADHD when they pay attention
Melatonin For Initial Insomnia In Stimulant-treated Pediatric ADHD
Funder
National Health and Medical Research Council
Funding Amount
$590,373.00
Summary
Does melatonin work for children with ADHD and initial insomnia? We will study children with ADHD and initial insomnia using N-of-1 trials. This is a trial in a single person, which allows them the opportunity to learn if melatonin is effective for them.We will compare the usual clinical trials (RCTs, which do not give individual results) with combined results from all the 270 patients who have done N-of-1 trials. Data from the first part of each person’s n-of-1 trial will form the RCT.
Genetic Influences On The Comorbidity Between Attention Deficit Hyperactivity Disorder And Substance Use
Funder
National Health and Medical Research Council
Funding Amount
$244,852.00
Summary
Substance use (SU) problems are more common among individuals with a history of ADHD. However, the reasons for this relationship are unclear. Our study will examine the extent to which this relationship is due to shared genetic influences using data collected during interviews about ADHD and SU in a large sample of young adult twins, their siblings and their parents. The results will aid in developing treatments targeting the symptoms of ADHD and SU concurrently.
Randomised Controlled Trial Investigation Of A Non-stimulant In Attention Deficit Hyperactivity Disorder
Funder
National Health and Medical Research Council
Funding Amount
$588,960.00
Summary
Atomoxetine (ATMX) is a viable non-stimulant alternative to treat Attention Deficit Hyperactivity Disorder (ADHD), however, clinicians require more objective information on its effectiveness. This is the first study to examine the effectiveness of ATMX using objective cognitive and emotion markers in ADHD. The outcomes from this project will be a significant step towards a 'personalised medicine' approach to ADHD, providing clinicians with increased options in the treatment of ADHD. ADHD is cons ....Atomoxetine (ATMX) is a viable non-stimulant alternative to treat Attention Deficit Hyperactivity Disorder (ADHD), however, clinicians require more objective information on its effectiveness. This is the first study to examine the effectiveness of ATMX using objective cognitive and emotion markers in ADHD. The outcomes from this project will be a significant step towards a 'personalised medicine' approach to ADHD, providing clinicians with increased options in the treatment of ADHD. ADHD is considered the most common neurodevelopmental or child psychiatric disorder. ADHD affects approximately 10% of children and adolescents, in other words, 'at least one in every classroom'. ADHD has a significant burden, including treatment costs, family stress, loss of productivity, increased risk of drug abuse and accidents. It is increasingly clear that new medications need to be evaluated to make ADHD treatment more effective and efficient. The vast majority of medicated ADHD individuals are treated with stimulants, which are controlled substances. A large number do not respond to stimulant treatment, and in others the potential for abuse remains. Some ADHD report negative feelings about taking stimulants and there is growing concern about increasing prescription rates. ATMX is a recently approved non-stimulant (therefore, non-controlled) to treat ADHD, with evidence of clinical effectiveness. Yet, the impact of ATMX on objective measures of a range of cognitive and emotional function has not been studied. Several lines of evidence indicate it is effective for these functions. ATMX has been shown to alleviate inhibitory capacity, while stimulants have not. Of the 30% of ADHD who do not respond to stimulants, the least responsive are those categorized as 'internalizing' types who show allied anxiety. Common disturbances may underlie abnormal inhibitory capacity and impaired emotional recognition in ADHD that is best treated with ATMX rather than stimulants.Read moreRead less